NNPA NEWSWIRE — With the most recent collaboration between Pfizer Rare Disease and the Black Press, the organizations embarked on a mission to educate and raise awareness to transthyretin amyloid cardiomyopathy – or ATTR-CM. “ATTR-CM is a rare, life-threatening, underrecognized, and underdiagnosed type of amyloidosis that affects the heart and it is associated with heart failure,” Dr. Kevin Williams, Pfizer’s chief medical officer, told the NNPA in a live interview.| By Stacy M. Brown, NNPA Newswire Senior National Correspondent @StacyBrownMedia It was less than four years ago that Pfizer Rare Disease teamed with the National Newspaper Publishers Association (NNPA) to assess the awareness of sickle cell disease, the challenges of living with it, and the importance of clinical trial participation. The partnership between the pharmaceutical […]
